Loss of MGAT3 retards the liver tumour burden when induced using diethylnitrosamine.59,60 Moreover, higher levels of MGAT3 has been observed in metastatic colorectal cancer cell lines.61 However, in breast cancer and hepatocarcinoma, MGAT3 loss has been shown to increase proliferation and invasion.62–65 Thus, MGAT3 plays a cancer-dependent promotor or suppressor role. Here, MGAT3 is linked to breast carcinoma.